| Subject: | Warning Added to Remicade (Infliximab) Prescribing Information |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Wed, 12 Jan 2005 - 10:00 am |
| Centocor, Inc., the makers of Remicade (Infliximab), a biological used as a medication to block tumor necrosis factor-alpha (TNF-alpha) in the human body. TNF-alpha acts as a chemical messenger in the body's immune system that signals other cells to cause inflammation. Excess inflammation however and can lead to tissue and joint damage. Remicade is used to treat diseases such as rheumatoid arthritis, Crohn's disease and ankylosing spondylitis. The use of Remicade is intended to lower the amount... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
Customizable Documents and Tools:
Related MCN Products:
|
|
StayAlert! provides immediate notification of regulatory body legislation impacting the healthcare industry, helping you to meet regulatory compliance. Subscribers are notified of any new or revised regulations, provided with a summary of the regulation, followed by an implementation action plan and/or policy. Designed as an e-mail "push" method for rapid customer notification of healthcare compliance issues, paired with interpretative analysis and practical application, the StayAlert!® Virtual Compliance Administrator™ saves you time and money. Other vendors have components of legislated requirements available online or on CD-ROM. However there is no other product that marries regulatory agency mandates with implementation tools, making the latest compliance information immediately available online. No other product provides an interpretative analysis, followed by a practical application tool, therefore providing users with an immediate solution to compliance problems. StayAlert! includes operational components for healthcare organizations, allowing complete facility compliance with mandated requirements, online. |
|
